Biotechnological application of Streptomyces for the production of clinical drugs and other bioactive molecules.
Journal
Current opinion in biotechnology
ISSN: 1879-0429
Titre abrégé: Curr Opin Biotechnol
Pays: England
ID NLM: 9100492
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
29
04
2022
revised:
29
06
2022
accepted:
30
06
2022
pubmed:
1
8
2022
medline:
14
9
2022
entrez:
31
7
2022
Statut:
ppublish
Résumé
Streptomyces is one of the most relevant genera in biotechnology, and its rich secondary metabolism is responsible for the biosynthesis of a plethora of bioactive compounds, including several clinically relevant drugs. The use of Streptomyces species for the manufacture of natural products has been established for more than half a century; however, the tremendous advances observed in recent years in genetic engineering and molecular biology have revolutionised the optimisation of Streptomyces as cell factories and drastically expanded the biotechnological potential of these bacteria. Here, we illustrate the most exciting advances reported in the past few years, with a particular focus on the approaches significantly improving the biotechnological capacity of Streptomyces to produce clinical drugs and other valuable secondary metabolites.
Identifiants
pubmed: 35908316
pii: S0958-1669(22)00096-9
doi: 10.1016/j.copbio.2022.102762
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102762Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M017702/1
Pays : United Kingdom
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.